TELA Bio (TELA) Expected to Announce Quarterly Earnings on Thursday

TELA Bio (NASDAQ:TELA) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $21.7820 million for the quarter. TELA Bio has set its FY 2025 guidance at EPS.Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). The firm had revenue of $20.20 million during the quarter, compared to analyst estimates of $20.67 million. TELA Bio had a negative net margin of 54.12% and a negative return on equity of 329.48%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Stock Down 5.8%

TELA opened at $1.29 on Wednesday. TELA Bio has a 1 year low of $0.86 and a 1 year high of $3.26. The firm has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.58. The company has a debt-to-equity ratio of 4.14, a quick ratio of 2.59 and a current ratio of 3.19. The company has a market cap of $51.11 million, a PE ratio of -1.15 and a beta of 0.89.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TELA Bio in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, TELA Bio presently has a consensus rating of “Hold” and an average target price of $4.50.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.